[CLSTR]
< Back to all clusters
[BUSINESS] · South Korea, United States · 4 sources

started · updated

Dong-A ST demonstrates topical potential for psoriasis treatment Icotrokinra

Dong-A ST Icotrokinra psoriasis treatment topical formulation drug delivery system

Dong-A ST has confirmed the potential to develop a topical formulation of Icotrokinra, an ingredient used for treating psoriasis, through non-clinical research. The company presented these findings at the AAPS PharmSci 360 international conference in New Orleans.

Icotrokinra is a macrocyclic peptide IL-23 receptor antagonist that selectively binds to interleukin-23 receptors to block inflammatory signals. While an oral version of the treatment received US FDA approval in March, Dong-A ST’s research focuses on expanding its application to a topical form that can be applied directly to the skin.

Through in vitro skin permeability and retention evaluations, the company’s Drug Delivery System (DDS) team secured a formulation capable of skin delivery. In animal models of skin inflammation, the formulation demonstrated anti-inflammatory effects by suppressing the gene expression of psoriasis-related inflammatory cytokines, specifically IL-17A, IL-17F, and IL-22.

Bank of America has projected that the maximum annual revenue for Icotrokinra-based oral treatments could reach $4.5 billion.

Entities

AAPS PharmSci 360 · Bank of America · Dong-A ST · New Orleans · US FDA

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

동아ST, 이코트로킨라 외용제 개발 가능성 확인 - 헬스이슈앤뉴스 [www.hin.company]
전문가들과 함께 만드는 신문 - 조세금융신문(www.tfnews.co.kr) [www.tfmedia.co.kr]
동아에스티, 건선 치료제 ‘이코트로킨라’ 외용제 개발 가능성 확인 [www.thebionews.net]
동아ST, AAPS PharmSci 360서 '이코트로킨라' 외용제 비임상 성과 발표 [www.bokuennews.com]